Its incidence and role in solid tumors is largely unknown, although, as previously pointed out, this reflects the limits of our prior technology. As discussed previously, homozygosity of tumor oncogenes in cancer cell lines is frequent, although the available information did not permit the distinction between MASI with CNGs or UPD as the mechanism. Using gene-specific and genome-wide approaches we found that UPD was LOUREIRIN-B frequent for three EGFR pathway genes, especially for KRAS gene. Relatively little data exists in the literature for KRAS CNGs in human tumors. Furthermore, KRAS homozygosity was observed independent of mutational status as previously described. The wild type allele of KRAS can also inhibit lung carcinogenesis in mice, providing a possible explanation for the frequent finding of UPD with mutant and wild type oncogenes. MASI has apparent biological and clinical significance. MASI at the genomic level was precisely maintained after transcription. While mutations, CNGs and allelic imbalance of mA and wA may all contribute to tumorigenesis, combinations of the three events may be more effective than any single event. Evidence for this concept was provided by our finding that the combination of mutation and CNGs acted synergistically to enhance ras GTPase activity. A recent report found that all KRAS mutations did not exert an equal effect on tumor cells. Cancer cell lines harboring KRAS mutations could be broadly divided into KRAS-dependent and KRAS-independent groups. The vast majority of KRAS-dependent lines exhibited focal KRAS CNGs, in contrast to KRAS-independent lines. This study provides further evidence that the combination of KRAS mutations and CNGs act synergistically. Our Mechlorethamine hydrochloride previous findings that EGFR mutations were associated with tumor initiation while EGFR CNG might be more regarded as a tumor progression event, provide further evidence of their co-operative role in tumorgenesis. Understanding the mechanism of MASI could elucidate new understandings of tumor biology and may contribute to the development of rational targeted therapies. MASI in its various forms is frequently 
present in mutant EGFR and KRAS tumor cells, and is associated with increased mutant allele transcription and gene activity. The frequent finding of mutations, copy number gains and MASI occurring together in tumor cells indicates that these three genetic alterations, acting together.